SNYRHealthcare · Medical DistributionSNYR Stock Forecast: Synergy CHC Corp. Price Predictions for 2026-2027
The 2 Wall Street analysts covering Synergy CHC Corp. hold a median 12-month price target of $3.75 — +2035.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 1 Aug 2026 — in the lower half.
SNYR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Synergy CHC Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Momentum (20): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Synergy CHC Corp. — and when they’d sell — is the membership.
SNYR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SNYR, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +2035.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 June 2026 | Ascendiant Capital | Maintains | Buy | — |
| 10 June 2026 | Ascendiant Capital | Maintains | Buy | $5.50 → $3.75 |
| 14 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 2 Feb 2026 | Ascendiant Capital | Initiates | Buy | — |
| 14 Nov 2025 | Roth Capital | Maintains | Buy | — |
| 21 Jan 2025 | Roth MKM | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SNYR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Synergy CHC Corp. (SNYR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 3.9×
- Price / sales
- 0.1×
- Price / book
- −0.1×
- EV / EBITDA
- −2.8×
Cheaper than 67% of US stocks
Cheaper than 97% of US stocks
Cheaper than 93% of US stocks
Cheaper than 75% of US stocks
- Revenue growth (YoY)
- −32.8%
- Earnings growth (YoY)
- −32.8%
- Gross margin
- 72.3%
- Operating margin
- −10.3%
- Net margin
- −57.0%
Higher than 8% of US stocks
Higher than 14% of US stocks
Higher than 85% of US stocks
Higher than 26% of US stocks
Higher than 9% of US stocks
- Return on equity
- 53.4%
- Return on assets
- −62.0%
- Dividend yield
- —
Higher than 93% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SNYR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| SNYRSynergy CHC Corp. | $2.6M | 47 |
| MEDSDataMeds AI, Inc. | $7.9M | 15 |
| COSMCosmos Health, Inc. | $12.9M | 23 |
| CMNDClearmind Medicine, Inc.* | $2.5M | 8 |
| ARTLArtelo Biosciences, Inc.* | $2.7M | 15 |
| CUPRCuprina Holdings (Cayman) Ltd.* | $2.7M | 4 |
| GRIGRI Bio, Inc.* | $2.4M | 21 |
* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNYR appears on the weeks it earns a place.
Frequently asked questions about SNYR stock
What is the SNYR stock price forecast for 2026-2027?
The 2 Wall Street analysts covering Synergy CHC Corp. have a median 12-month price target of $3.75, with estimates ranging from $3.75 to $3.75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SNYR stock a buy right now?
Of the 2 analysts covering Synergy CHC Corp., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Synergy CHC Corp. 47 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SNYR?
As at 1 Aug 2026, Synergy CHC Corp. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
Will SNYR stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +2035.5% from the last close, and Ticker Nerd's factor model ranks Synergy CHC Corp. 47 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SNYR stock forecast for 2030?
No analyst covering Synergy CHC Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNYR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.75 to $3.75 over the next 12 months.
What does Synergy CHC Corp. do?
Synergy CHC Corp. is an innovative company that specializes in marketing and distributing consumer healthcare products.
About Synergy CHC Corp.
Synergy CHC Corp. is an innovative company that specializes in marketing and distributing consumer healthcare products. Its product portfolio encompasses a wide range of health and wellness categories, including dietary supplements, skin care, and over-the-counter remedies. The company's primary function is to develop and promote products that cater to the increasing consumer demand for health-conscious options that support active lifestyles. Synergy CHC Corp. actively participates in the consumer healthcare sector by striving to deliver effective, high-quality products using both traditional and digital marketing strategies. With its presence in multiple international markets, the company seeks to leverage global consumer trends towards wellness and preventive health. Synergy CHC Corp.'s contribution to the financial market is significant as it provides investors with exposure to the rapidly growing health and wellness industry, characterized by strong consumer interest and expansive opportunities for product innovation and market expansion.
CEO Mr. Jack Ross · 28 employees · United States · https://synergychc.com